The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.
The role of microRNAs in the resistance to colorectal cancer treatments
Corresponding Author(s) : R Amirkhah
Cellular and Molecular Biology,
Vol. 61 No. 6: Advances in molecular oncology: Closer analysis of recent breakthroughs
Abstract
Colorectal cancer (CRC) is one of the leading cancer-related causes of death in the world. Several approaches such as surgery, chemotherapy, radiotherapy, targeted therapy, or combinations thereof have been used to treat CRC patients. However, the fact that many patients develop a drug resistance during the course of the treatment is a major obstacle. Understanding the mechanisms underlying resistance is critical in order to develop more effective targeted treatments. Recently, several studies have reported on the regulatory role of microRNAs (miRNAs) in the response to anti-cancer drugs and suggested them as a source of predictive biomarkers for the purpose of patient stratification and for the prognosis of treatment success. For example, overexpressing miR-34a, a master regulator of tumor suppression attenuates chemoresistance to 5-FU by downregulating silent information regulator 1 (SIRT1) and E2F3. MRX34, a miR-34a replacement is the first synthetic miRNA mimic to enter clinical testing. MiR-34a antagonizes cancer stemness, metastasis, and chemoresistance processes that are necessary for cancer viability. This example shows that miRNAs are coming into focus for the design of enhanced cancer therapies that aim to sensitise tumor cells for anti-cancer drugs. In this review, we provide an overview on the role of miRNAs in the resistance to current colorectal cancer therapies. Furthermore, we discuss the value of miRNAs as biomarkers for predicting chemosensitivity and their potential to enhance treatment strategies.
Keywords
Colorectal cancer
MicroRNA
Chemotherapy
Radiotherapy
Biomarker.
Amirkhah, R., Farazmand, A., Irfan-Maqsood, M., Wolkenhauer, O., Wolkenhauer, O., & Schmitz, U. (2015). The role of microRNAs in the resistance to colorectal cancer treatments. Cellular and Molecular Biology, 61(6), 17–23. Retrieved from http://mail.cellmolbiol.org/index.php/CMB/article/view/719
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX